These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 2529493)
21. A drug information-ADR collection network: the French system. Dangoumau J; Lagier G; Royer RJ Drug Inf J; 1986; 20(3):337-46. PubMed ID: 10317774 [No Abstract] [Full Text] [Related]
22. [Pharmacovigilance in the framework of recording and control of drugs in the United Kingdom]. Dunlop D Therapie; 1974; 29(6):799-804. PubMed ID: 4462229 [No Abstract] [Full Text] [Related]
23. [Cutaneous side-effects in drug assessment]. Jean-Pastor MJ Therapie; 2002; 57(3):265-8. PubMed ID: 12422540 [TBL] [Abstract][Full Text] [Related]
24. Highlights of the 22nd French pharmacovigilance meeting. Prescrire Int; 2002 Feb; 11(57):21-3. PubMed ID: 11985373 [TBL] [Abstract][Full Text] [Related]
25. Is there any relationship between actual benefit and added value of drugs and pharmacovigilance alerts? Tavassoli N; Montastruc JL Br J Clin Pharmacol; 2009 Jul; 68(1):124-5. PubMed ID: 19660011 [No Abstract] [Full Text] [Related]
26. [Drug-induced interstitial lung diseases]. Bonniaud P; Georges M; Favrolt N; Camus P Rev Prat; 2014 Sep; 64(7):951-6. PubMed ID: 25362778 [TBL] [Abstract][Full Text] [Related]
27. [Evaluation of the pharmacovigilance follow-up of zidovudine]. Gimenez S; Bagheri H; Marchou B; Massip P; Lafont J; Sorbette F; Armengaud M; Montastruc JL Therapie; 1990; 45(5):407-9. PubMed ID: 2260033 [TBL] [Abstract][Full Text] [Related]
28. A survey of adverse drug reaction reporting programs in select hospitals. Case RL; Guzzetti PJ Hosp Pharm; 1986 May; 21(5):423-6, 431-4, 438. PubMed ID: 10276799 [TBL] [Abstract][Full Text] [Related]
29. Features of the French postmarketing drug surveillance system. Application to cutaneous effects of nonsteroidal antiinflammatory drugs. Albengres E J Rheumatol Suppl; 1988 Oct; 17():20-3. PubMed ID: 3204616 [TBL] [Abstract][Full Text] [Related]
30. [Safety of medicinal products and reporting of adverse drug reactions]. Skibicka I; Maciejczyk A Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675 [TBL] [Abstract][Full Text] [Related]
31. [Dealing with adverse drug reactions in dentistry. Procedures on encountering adverse drug reactions and goal of the Swiss Pharmacovigilance system]. Egger SS; Krähenbühl S; Schlienger RG Schweiz Monatsschr Zahnmed; 2005; 115(12):1209-18. PubMed ID: 16408825 [TBL] [Abstract][Full Text] [Related]
33. SAFETY PROFILE OF OCRIPLASMIN FOR SYMPTOMATIC VITREOMACULAR ADHESION: A Comprehensive Analysis of Premarketing and Postmarketing Experiences. Hahn P; Chung MM; Flynn HW; Huang SS; Kim JE; Mahmoud TH; Sadda SR; Dugel PU Retina; 2015 Jun; 35(6):1128-34. PubMed ID: 25635575 [TBL] [Abstract][Full Text] [Related]
34. French pharmacovigilance: Missions, organization and perspectives. Vial T Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832 [TBL] [Abstract][Full Text] [Related]
35. [Evaluation of drug-induced hepatic complications collected by the French drug surveillance organization]. Jean-Pastor MJ; Jouglard J Therapie; 1984; 39(5):493-500. PubMed ID: 6506005 [No Abstract] [Full Text] [Related]
36. [Misuse of drugs: conclusions of the pharmacovigilance workshops at La Baule, France]. Fermont I; Therapie; 2002; 57(3):283-8. PubMed ID: 12422543 [TBL] [Abstract][Full Text] [Related]
37. New drugs: watch out for unexpected adverse effects. Prescrire Int; 2002 Oct; 11(61):150-1. PubMed ID: 12378747 [TBL] [Abstract][Full Text] [Related]
38. Veterinary pharmacovigilance in the European context. Keck G Ann Ist Super Sanita; 1992; 28(4):425-8. PubMed ID: 1303032 [TBL] [Abstract][Full Text] [Related]